SUMMARY In primary biliary cirrhosis (PBC) liver copper retention occurs as a complication of cholestasis. By analogy with Wilson's disease, it has been suggested that copper retention is hepatotoxic in PBC, and this has been the rationale for the use of D-penicillamine in this disease. The hypothesis that copper is hepatotoxic in PBC has not been tested and in this study we have evaluated the role of liver copper retention in the pathogenesis of PBC. Sixty-four patients with PBC have been studied. Fifty-four had increased liver copper concentrations. Liver cell synthetic function was well preserved. All the patients had normal prothrombin times, and only two had subnormal serum albumin concentrations. There was no correlation between liver copper concentrations and the degree of liver cell damage assessed biochemically (aspartate transaminase), and histologically. Electron microscopy was performed on liver biopsies from five patients with markedly increased liver copper concentrations. The liver cell ultrastructure was compatible with cholestasis. Liver cells contained electron dense lysosomes, which were shown to contain copper and sulphur by x-ray probe microanalysis. The Wilson's disease, copper cytotoxicity is associated with characteristic organelle abnormalities seen on electron microscopy.6-9 To determine whether these organelle abnormalities occur in PBC, electron microscopy was performed on liver biopsies from five PBC patients with markedly raised liver copper concentrations. The elemental composition of liver cell lysosomes seen on electron microscopy were studied by x-ray probe microanalysis. For this purpose, 2000 A (200 nm) sections were cut from Epon blocks using glass knives. The sections were picked up on nylon grids supported by a carbon holder, and unstained sections were probed using a Keevex energy dispersive spectrometer, and a Jeol 100 C electron microscope provided with a Jeol ASID scanning attachment. The material was studied in the scanning transmission mode at 100 kV using a take-off angle of 300. The counting time was 50 s, at a counting rate of 1500 counts/s. In order to detect primarily copper, sulphur, and zinc, the window was set at a width of 9 channels. There was no contribution to the spectra from the microscope.
Results
The mean liver copper concentration was 321 ,ug/g dry weight (range 32-1388 ug/g; normal adult less than 55 ,ug/g). Fifty-four patients (85%) had increased liver copper (Fig. 3) .
The presence of copper and sulphur was demonstrated by x-ray probe analysis of these lysosomes (Fig. 3) .
Discussion
In PBC, the primary pathogenic process is directed against small intrahepatic bile ducts. Copper re- (Table) . The copper is present in both lysosomes and the cytosol,6 71617 and can be stained with rubeanic acid.6 71318 The sulphur detected with copper in PBC lysosomes probably reflects the presence of the sulphur-rich copper-associated protein which stains with orcein,19 and is present in both PBC13 and neonatal" liver. The staining characteristics and subcellular distribution of liver copper in PBC is similar to the neonate, where copper is not thought to be hepatotoxic.16 18 It is likely that at liver copper concentrations occurring in PBC, the copper is retained in a non-toxic form.
This study stresses that there is no simple analogy between liver copper rentention in PBC and Wilson's disease. Wilson's disease is an inborn error of copper metabolism, whereas in PBC, cholestasis and biliary cirrhosis dominate the clinical and biochemical evolution of the disease, with liver copper retention occurring as a complication of cholestasis. In patients with PBC and increased liver copper concentrations, liver cell function is preserved and there is no positive evidence to suggest that copper retention in PBC is an important factor in the pathogenesis of the disease. Copper chelation with Dpencillamine is effective treatment in Wilson's disease. The potetial value of this drug as a purely copper chelating agent in PBC is questionable.20 Penicillamine causes a fall in immune complexes and immunoglobulins in PBC,21 and the immunological rather than the copper chelating effects of this drug may therefore be of greater importance in treatment.22 0 Epstein is supported by Advisory Services (Clinical and General) and Mr A Chester Beatty.
